Arthritis, Psoriatic

• 

  Subject Areas on Research

  • A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. 
  • Adiposity in Juvenile Psoriatic Arthritis. 
  • Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. 
  • Contraception methods used by women with rheumatoid arthritis and psoriatic arthritis. 
  • Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. 
  • Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11. 
  • Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014. 
  • GRAPPA 2018 Project Report. 
  • Infliximab treatment for rheumatic disease: clinical and radiological efficacy. 
  • International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. 
  • Let's Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting. 
  • PSORS2 is due to mutations in CARD14. 
  • Patient participation in psoriasis and psoriatic arthritis outcome research: a report from the GRAPPA 2013 Annual Meeting. 
  • Proceedings of the GRAPPA 2016 Retreat. 
  • Prologue: 2018 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). 
  • Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. 
  • Psoriatic arthritis of the foot and ankle: analysis of joint involvement and diagnostic errors. 
  • Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. 
  • Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. 
  • Retinal venular calibre is increased in patients with autoimmune rheumatic disease: a case-control study. 
  • Secukinumab (AIN-457) for the treatment of Psoriasis. 
  • Tackling Patient Centricity: A Report from the GRAPPA 2016 Annual Meeting. 
  • The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. 
  • The Patient Research Partner Network Matures: A Report from the GRAPPA 2017 Annual Meeting. 
  • The effects of cultural background on patient-perceived impact of psoriatic arthritis - a qualitative study conducted in Brazil and France. 
  • Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016.